Methotrexate for rheumatoid arthritis patients who are on hemodialysis

Hasanein Al-Hasani; Euthalia Roussou

doi:10.1007/s00296-011-2041-5

Methotrexate for rheumatoid arthritis patients who are on hemodialysis

Rheumatol Int. 2011 Dec;31(12):1545-7. doi: 10.1007/s00296-011-2041-5. Epub 2011 Jul 22.

Authors

Hasanein Al-Hasani¹, Euthalia Roussou

Affiliation

¹ Barts and The London School of Medicine and Dentistry, Turner Street, London, E1 2AD, UK.

PMID: 21833520
DOI: 10.1007/s00296-011-2041-5

Abstract

Methotrexate (MTX) can be toxic to patients suffering from end stage renal disease (ESRD) on hemodialysis even at low doses. This increase in toxicity is more notable in terms of bone marrow suppression in the form of pancytopenia. Many methods of elimination including dialysis itself have been proven ineffective, and alternate treatments with anti-TNF alpha blockers can be considered.

Publication types

Review

MeSH terms

Antirheumatic Agents / adverse effects*
Antirheumatic Agents / pharmacokinetics
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / complications
Arthritis, Rheumatoid / drug therapy*
Bone Marrow / drug effects
Humans
Kidney Failure, Chronic / complications
Kidney Failure, Chronic / physiopathology*
Methotrexate / adverse effects*
Methotrexate / pharmacokinetics
Methotrexate / therapeutic use
Pancytopenia / chemically induced
Renal Dialysis*
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Withholding Treatment

Substances

Antirheumatic Agents
Tumor Necrosis Factor-alpha
Methotrexate